AMSTERDAM, The Netherlands, August 5 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it will release its financial results for the first half year of 2008 on Wednesday, August 13, 2008 at noon Central European Time (CET). To discuss these results, the company will conduct a conference call at 2:00 p.m. CET. Netherlands dial in: 0800-949-4517 (toll free); US dial in: +1-866-291-4166 (toll free); UK dial in: +44-207-107-0611. To listen to the conference call live via the internet, visit the investor relations portion of the AMT website at http://www.amtbiopharma.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases, especially the ones that are caused by one faulty gene. AMT currently has a product pipeline with seven products at different stages of development.

PRN NLD

For information: Andre Verwei, CFO, +31-20-566-5686, a.verwei@amtbiopharma.com; Rob Janssen, Director Corporate Communications & Investor Relations, +31-20-566-7509, r.janssen@amtbiopharma.com